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Objectives: Data on quinolone consumption in the community were collected from 30 EU/European Economic
Area (EEA) countries over two decades. This article reviews temporal trends, seasonal variation, presence of
change-points and changes in the composition of main subgroups of quinolones.
Methods: For the period 1997–2017, data on consumption of quinolones, i.e. ATC group J01M, in the community
and aggregated at the level of the active substance, were collected using the WHO ATC/DDD methodology (ATC/
DDD index 2019). Consumption was expressed in DDD per 1000 inhabitants per day and in packages per 1000
inhabitants per day. Quinolone consumption was analysed by subgroups based on pharmacokinetic profile, and
presented as trends, seasonal variation, presence of change-points and compositional changes.
Results: In 2017, quinolone consumption in the community expressed in DDD per 1000 inhabitants per day
varied by a factor of 8.2 between countries with the highest (Bulgaria) and the lowest (Norway) consumption.
The second-generation quinolones accounted for >50% of quinolone consumption in most countries. Quinolone
consumption significantly increased up to 2001, and did not change significantly afterwards. Seasonal variation
increased significantly over time. Proportional consumption of third-generation quinolones significantly
increased over time relative to that of second-generation quinolones, while proportional consumption of both
third- and second-generation quinolones significantly increased relative to that of first-generation quinolones.
Levofloxacin and moxifloxacin represented >40% of quinolone consumption in the community in southern
EU/EEA countries.
Conclusions: Quinolone consumption in the community is no longer increasing in the EU/EEA, but its seasonal
variation continues to increase significantly as is the proportion of quinolones to treat respiratory infections.
Introduction
This article presents data from the European Surveillance of
Antimicrobial Consumption Network (ESAC-Net,1 formerly
ESAC) on consumption of quinolones in the community (i.e. pri-
mary care sector) for 30 EU/European Economic Area (EEA)
countries in 2017. It updates previous ESAC studies published
in 2006 and 2011, and in doing so it provides updated compar-
able and reliable information on antibiotic consumption
that can aid in fighting the global problem of antimicrobial re-
sistance.2,3 In 2017, quinolones represented 9.5% of antibiotic
consumption in the community.4 As in the previous series, qui-
nolones were classified in three generations as introduced by
Ball,5 based on their chemical structure and antimicrobial activ-
ity.2,3 The objective of this study was to analyse temporal
trends, seasonal variation and the presence of change-points
in quinolone consumption in the community for the period
VC The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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1997–2017, as well as to analyse the composition of quinolone
consumption over time.
Methods
The methods for collecting and analysing the data are described in the
introductory article of this series.6 In summary, data on the consumption of
quinolones, i.e. quinolone antibacterials (ATC group J01M), and aggregated
at the level of the active substance, were collected using the WHO ATC/DDD
methodology (WHO/ATC index 2019)6 and expressed in DDD per 1000
inhabitants per day. In addition, where data were available, quinolone
consumption was also expressed in packages per 1000 inhabitants per
day. For quinolones, a classification according to chemical structure and
antimicrobial activity, subdividing quinolones into three generations
was used to assess quinolone consumption in the community in more
detail (Table 1).5
There are 28 unique ATC codes for quinolones in the ATC/DDD index
2019. Compared with previous descriptions of the consumption of qui-
nolones in the community, two additional substances, i.e. sitafloxacin
(J01MA21) and nemonoxacin (J01MB08) have been assigned an ATC
code by the WHO (Table 1).
The evolution of the number of DDD per package over time was
assessed using a linear mixed model. The temporal trend, seasonal
variation and presence of change-points in quinolone consumption
were assessed using a non-linear change-point mixed model fitted
to quarterly data expressed in DDD per 1000 inhabitants per day
from 1997 to 2017.7 The relative proportions of the main subgroups
were assessed through a compositional data analysis modelling
yearly data expressed in DDD per 1000 inhabitants per day from 1997
to 2017.8
Results
An overview of consumption of quinolones (ATC J01M) in the com-
munity, expressed in DDD and packages per 1000 inhabitants per
day for all participating countries between 1997 and 2017 is avail-
able as Supplementary data at JAC Online (Tables S1 and S2,
respectively).
Quinolone consumption in the community in 2017
In 2017, four substances accounted for 90% of quinolone con-
sumption in the community expressed in DDD per 1000 inhabi-
tants per day: ciprofloxacin (48.6% in 2017 compared with 50.8%
in 2009), levofloxacin (28.8% in 2017 compared with 11.8% in
2009), norfloxacin (10.4% in 2017 compared with 18.2% in 2009)
and moxifloxacin (7.2% in 2017 compared with 7.4% in 2009)
(Table 1).
Figure 1 shows quinolone consumption, as well as the con-
sumption of the three generations of quinolones, in the commu-
nity expressed in DDD per 1000 inhabitants per day in 2017.
Quinolone consumption in the community varied by a factor of 8.2
between countries with the highest (2.86 DDD per 1000 inhabi-
tants per day in Bulgaria) and the lowest (0.35 DDD per 1000
inhabitants per day in Norway) consumption, which was higher
than in 2009 (factor of 7.5, from 3.61 DDD per 1000 inhabitants per
day in Italy to 0.48 DDD per 1000 inhabitants per day in the United
Kingdom). We observed substantial inter-country variability in the
consumption of first- and third-generation quinolones.
Consumption of second-generation quinolones showed slightly
less variability between countries (Table S1).
In 2017, first-generation quinolones (mostly norfloxacin) repre-
sented the most consumed quinolone subgroup only in Croatia,
and represented >20% of quinolone consumption in the commu-
nity in Estonia, Lithuania, Poland and Romania (total care data).
Pipemidic acid was used in five countries. Among the other first-
generation quinolones, nalidixic acid was only reported in Romania
(total care data) and flumequine was only used in France.
Second-generation quinolones were by far the most widely
consumed quinolones in EU/EEA countries. Their consumption
exceeded 50% (median 85%) of quinolone consumption in
the community in all countries except Croatia. Ciprofloxacin
was the most consumed second-generation quinolone in 24
countries; levofloxacin was the most consumed in Bulgaria,
Cyprus (total care data), Hungary and Italy; and ofloxacin was
the most consumed in France.
Table 1. Clinical classification of quinolones (J01M; ATC/DDD index 2019)
First-generation Second-generation Third-generation
J01MA06 Norfloxacina J01MA01 Ofloxacina J01MA05 Temafloxacinb
J01MB01 Rosoxacinb J01MA02 Ciprofloxacina J01MA13 Trovafloxacinb
J01MB02 Nalidixic acid J01MA03 Pefloxacin J01MA14 Moxifloxacina
J01MB03 Piromidic acidb J01MA04 Enoxacin J01MA15 Gemifloxacinb
J01MB04 Pipemidic acid J01MA07 Lomefloxacin J01MA16 Gatifloxacinb
J01MB05 Oxolinic acidb J01MA08 Fleroxacinb J01MA17 Prulifloxacin
J01MB06 Cinoxacin J01MA09 Sparfloxacinb J01MA18 Pazufloxacinb
J01MB07 Flumequine J01MA10 Rufloxacin J01MA19 Garenoxacinb
J01MB08 Nemonoxacinc J01MA11 Grepafloxacinb J01MA21 Sitafloxacinc
J01MA12 Levofloxacina
Bold type indicates that consumption was part of the top 90% of the community consumption of quinolones (J01M) in 28 EU/EEA countries in 2017;
Italic type indicates that no consumption of this quinolone was reported in 28 EU/EEA countries in 2017.
aConsumption was part of the top 90% of the community consumption of quinolones (J01M) in 30 EU/EEA countries in 2009.
bNo consumption of this quinolone was reported in 30 EU/EEA countries in 2009.
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Among the third-generation quinolones, only moxifloxacin and
prulifloxacin were widely consumed in EU/EEA countries during
1997–2017. Moxifloxacin was the most consumed third-gener-
ation quinolone in all countries except Italy where prulifloxacin
was the most consumed. Sweden also reported limited consump-
tion of temafloxacin.
Figure 2 shows quinolone consumption in the community
expressed in packages per 1000 inhabitants per day for 20 EU/EEA
countries in 2017. Czechia ranked 13th for its quinolone consump-
tion in DDD per 1000 inhabitants per day and 8th in packages per
1000 inhabitants per day (Table 2). The number of DDD per pack-
age ranged from 3.6 in Czechia to 9.1 in Sweden and was higher
than in 2009 (from 2.2 in Italy to 8.5 in Sweden in 2009). In the
EU/EEA countries, the number of DDD per package did not change
significantly over time during 1997–2017.
Longitudinal data analysis, 1997–2017
The best fit was obtained for a model including two change-points:
one in the third quarter of 2001 and another in the third quarter of
2010. The final model fits the observed data well (Figure S1). The
longitudinal data analysis estimated an average quinolone con-
sumption in the EU/EEA of 1.177 (SE 0.187) DDD per 1000 inhabi-
tants per day in the first quarter of 1997. In addition, the analysis
showed a significant seasonal variation with an amplitude of
0.079 (SE 0.032) DDD per 1000 inhabitants per day, which
increased significantly over time (!0.001, SE 0.0002, DDD per
1000 inhabitants per day per quarter). Quinolone consumption sig-
nificantly increased (!0.014, SE 0.005, DDD per 1000 inhabitants
per day per quarter) between 1997 and the third quarter of 2001.
After this first change-point, no significant change was observed
(!0.007, SE 0.006, DDD per 1000 inhabitants per day per quarter
until the third quarter of 2010, after which there was a decrease of
#0.003, SE 0.008, DDD per 1000 inhabitants per day per quarter)
(Figure 3).
Based on the fitted model, community quinolone consumption
in 1997 was significantly higher than average in Belgium, Greece,
Italy, Luxembourg, Portugal and Spain, and significantly lower
than average in Denmark, Finland, Hungary, Iceland, Lithuania
and the United Kingdom (observed profiles shown in Figure S2
and S3). The seasonal variation was significantly larger than aver-
age in Belgium, Germany, Hungary, Italy, Luxembourg, Portugal
and Spain, and significantly smaller than average in Cyprus (total
care data), Denmark, Estonia, Finland, Iceland, Ireland, the
Netherlands and the United Kingdom. The increase in quinolone
consumption between 1997 and the third quarter of 2001 was
significantly larger than average in Belgium and Hungary. The in-
crease between the last quarter of 2001 and the third quarter of
2010 was significantly larger than average in Cyprus (total care
data), Italy, Lithuania and Slovakia. The decrease in quinolone
consumption between the last quarter of 2010 and 2017 was
significantly larger than average in Italy and Portugal.
Table S1 provides an overview of quinolone consumption in the
community in the participating countries between 1997 and 2017.
Quinolone consumption decreased in several countries. This de-
crease was the highest in Portugal, but also considerable in Italy
and France. The largest increases in quinolone consumption in the
community were observed for Cyprus, Romania, Bulgaria, Hungary
and Malta. The seasonal variation in quinolone consumption is
shown in Figures S2 and S3. In all countries except Belgium

























































































































































Figure 1. Consumption of quinolones (ATC J01M) in the community, expressed in DDD (ATC/DDD index 2019) per 1000 inhabitants per day, 30 EU/
EEA countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e. community and
hospital sector combined, are used.
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(winter) quarters did not exceed the mean consumption in the se-
cond and third (summer) quarters by >20%. The high seasonal
variation in Belgium and Italy resulted from the relatively frequent
consumption of third-generation quinolones in the winter quar-
ters. Moxifloxacin and levofloxacin showed the highest seasonal
variation. Moxifloxacin consumption was >50% higher in winter
quarters compared with summer quarters in Austria, Belgium,
Estonia, Italy, Latvia, Luxembourg and Portugal. Levofloxacin
consumption was >50% higher in winter quarters compared with
summer quarters in Austria, Belgium, Croatia, Denmark, Estonia
and Finland.
Compositional data analysis, 1997–2009
The proportional consumption of third-generation quinolones sig-
nificantly increased over time relative to that of second-generation
quinolones, whilst the consumption of both second- and third-
generation quinolones significantly increased relative to that of
first-generation quinolones (Table 3).
Trends of proportional consumption in individual countries are
shown in Figure S4. When comparing the composition of quinolone
consumption in 2017 with that in 2009, the proportion of first-
generation quinolones decreased for most of the participating
countries with the largest decreases observed for Czechia
(#28.69%; 2015 data), Cyprus (#3.48%; total care data),
the Netherlands (#21.07%), Poland (#19.45%) and France
(#15.51%). These decreases can mainly be explained by decreas-
ing norfloxacin consumption. For Italy and Lithuania, the decrease
also resulted from decreasing consumption of pipemidic acid. In
most countries, the decrease in the proportion of first-generation
quinolones was matched by a similar increase in the consumption
of second-generation quinolones. The largest increases in the pro-
portion of second-generation quinolones were observed for
Czechia (!28.16%; 2015 data), Cyprus (!25.09%; total care data),
the Netherlands (!21.80%) and France (!21.37%). The proportion
of third-generation quinolones showed both increases and
decreases, with the largest increases observed for Greece
(!18.67%), Austria (!10.86%) and Poland (!6.42%), and the larg-
est decreases for Portugal (#11.39%), Malta (#9.25%) and Italy
(#8.48%).
The proportional consumption of levofloxacin and moxifloxacin
combined out of quinolone consumption in the community is
shown in Figure S5. In most countries, this proportion has been
increasing since they were introduced. In 2017, the proportion of
levofloxacin and moxifloxacin combined represented >50% of
quinolone consumption in the community in Bulgaria, Cyprus
(total care data), Hungary and Italy, >40% in Belgium, Malta and
Spain, and >30% in Austria, Finland, Germany, Greece, Portugal
and Romania (total care data).
Discussion
This study describes consumption of quinolones in the community
in the EU/EEA, which has been described as one of the fastest
growing antibiotic classes since the start of surveillance of anti-
microbial consumption in Europe in 1997.2,3 The longitudinal data
analysis shows this increase has in general stopped. Yet, variation
between countries has increased, with Bulgaria having the highest
quinolone consumption in the community (mainly levofloxacin) in


















































































































Figure 2. Consumption of quinolones (ATC J01M) in the community, expressed in packages per 1000 inhabitants per day, 20 EU/EEA countries, 2017.
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showing a substantial increase in quinolone consumption in the
community compared with 2009.
In 2017, the consumption of quinolones out of all antibacte-
rials for systemic use (J01) ranged from 2.46% in Norway
to 21.49% in Cyprus.4 In European countries that are not
part of the ESAC-Net but covered by the WHO Europe
Antimicrobial Medicines Consumption (AMC) Network, a similar
range was observed, i.e. from 0.5% (Kyrgyzstan) to 17.8%
(Kazakhstan) of total, i.e. community and hospital sector com-
bined, consumption.9
Ciprofloxacin remained the most consumed quinolone in most
countries. Yet, an emerging trend to consume more levofloxacin
and moxifloxacin, mainly in countries with a high quinolone
consumption, should be noted (Figure S5). Moreover, seasonal
variation increased in the EU/EEA over time during 1997–2017 sug-
gesting increasing inappropriate use of quinolones to treat respira-
tory tract infections. Quinolones must be considered as broad-
spectrum antibiotics and are not recommended as first-line
antibiotics for the treatment of respiratory tract infections in the
community. The potential small superiority of third-generation
quinolones, as compared with penicillin and macrolides, for the
treatment of respiratory tract infections should be balanced
against concerns of selection pressure and cost.10 In addition,
ciprofloxacin is contraindicated for the treatment of community-
acquired pneumonia because it is not active against Streptococcus
pneumoniae.11 Quinolone consumption in DDD per 1000 inhabi-
tants as well as seasonal variation of quinolone consumption are
among the final set of 12 ESAC drug-specific quality indicators
for outpatient antibiotic consumption in Europe.12 The 2017
values for the drug-specific quality indicators are reported in an
accompanying article.13 The ESAC disease-specific quality indica-
tors for outpatient antibiotic use also focus on quinolone consump-
tion, with an upper limit of 5% quinolone prescriptions in patients
being prescribed an antibiotic for any of the seven listed
indications.14 In Belgium for example, the National Institute for
Health and Disability Insurance (NIHDI) restricted the prescription
of quinolones to certain diagnoses (mainly urinary tract) and
conditions.15,16 A patient will only receive reimbursement for a
quinolone prescription in case of adherence to these restrictions.
It is too soon to evaluate this policy change with the available
ESAC-Net data, but preliminary results show that between 2017
and 2018 the consumption of fluoroquinolones in the community
declined by 46% when based on reimbursement data but only by
25% based on sales data.17 This suggests that such policy inter-
ventions need careful implementation as prescribing and choice of
an antibiotic according to the guidelines is an individual doctor’s
decision.
Based on a recommendation from EMA and following the sus-
pension of the marketing authorization of medicines containing
cinoxacin, flumequine, nalidixic acid, and pipemidic acid, the
European Commission decided to restrict the use of the remaining
fluoroquinolones because of the risk of disabling and potentially
permanent side-effects. According to the EMA’s recommendation,
fluoroquinolones should not be used (a) to treat infections that
might get better without treatment or infections that are not se-
vere (such as throat infections); (b) to treat non-bacterial infec-
tions, e.g. non-bacterial (chronic) prostatitis; (c) to prevent
traveller’s diarrhoea or recurring lower urinary tract infections
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treat mild or moderate bacterial infections unless other antibacter-
ial medicines commonly recommended for these infections can-
not be used.18
As quinolone consumption should be restricted and mainly
reserved for well-defined indications, the high consumption and
seasonal variation of quinolones in the community observed in
some countries probably indicates non-adherence to prescribing
guidelines. From a public health perspective, this is an important
consideration, as excessive and inappropriate use of quinolones is
associated with the development of quinolone resistance, requires
more resources and exposes patients to the additional risk of side
effects.19,20
All quinolones (ATC J01M) are listed as Watch group antibiotics
in the 2019 WHO Access, Watch or Reserve (AWaRe) classification
list.21 The continuous monitoring of quinolone consumption in the
community can help to assess the impact of future interventions
promoting better use of these antibiotics.
For a more-detailed discussion on the limitations of the col-
lected data, we refer to the article on antibacterials for systemic
use, included in this series.6 For a discussion on the limitations of
the statistical approach used in this study and potential explana-
tions for the common change-points detected through these anal-
yses, we refer to the tutorial included in this series.7
In conclusion, even though community quinolone consumption
in the EU/EEA stopped increasing, there is still substantial seasonal
variation, which suggests inappropriate prescribing of quinolones
in the community in many countries. This could be a target for fu-
ture awareness campaigns for more-prudent use of antibiotics.
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Figure 3. Estimated trend (solid line) and linear trend (dashed line) of consumption of quinolones (ATC J01M) in the community based on quarterly
data, 25 EU/EEA countries, 1997–2017. b0, predicted consumption in the first quarter of 1997; b1, predicted increase (if positive)/decrease (if negative)
in consumption per quarter; b2, predicted difference in slope after versus before the first change-point; b3, predicted difference in slope after versus
before the second change-point; b4, predicted difference in slope after versus before the third change-point; b0
S, predicted amplitude of the upward
winter and downward summer peak in consumption; b1
S, predicted increase (if positive)/decrease (if negative) of the amplitude of the upward winter
and downward summer peak in consumption per quarter; d, shift in timing of the upward winter and downward summer peak from one year to an-
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